drugset
drugset / Trial / NCT06566768

Study to Evaluate Drug Levels of Various Solid Gastro-retentive Formulations of Deucravacitinib (BMS-986165) in Healthy Participants

NCT06566768 ↗

Phase 1 Completed 52 enrolled Bristol-Myers Squibb
Non-randomizedSequentialOpen-labelTreatment

Summary

The purpose of this study is to identify drug levels of gastro-retentive (GR) formulations which prolong retaining time in the stomach of deucravacitinib (BMS-986165) in Healthy Participants.

Timeline

Start
2024-10-07
Primary completion
2025-06-13
Completion
2025-06-13

Drugs

EvaluationDrugModalityDoseRoute
Subject CRAVACITINIB Small molecule — Oral

Indications

No indication recorded.